ProQR, Galapagos Enter R&D Alliance

ProQR Therapeutics has entered into a research collaboration with Galapagos to discover novel Axiomer Editing Oligonucleotides (EONs) against fibrosis targets selected by Galapagos.

ProQR is developing its RNA platform technology in areas of ophthalmology, cystic fibrosis and dystrophic epidermolysis bullosa. Through a collaboration with Amylon Therapeutics, the platform is also being developed for CNS indications including HCHWA-D. Recently, validation and expansion of the platform included positive results in clinical trials in cystic fibrosis and initiating a clinical trial in Leber’s congenital amaurosis.

“In this collaboration we will explore a novel application of our Axiomer technology to Galapagos’ fibrosis targets,” said Daniel A. de Boer, chief executive officer of ProQR. “We look forward to
working closely with the team at Galapagos. With their leadership in the discovery of novel drug targets and our platform technology and know-how, we can make a meaningful impact together.”

Onno van de Stolpe, chief executive officer at Galapagos said, “With our vast experience in the discovery of novel drug targets, we believe ProQR’s Axiomer technology can be applied to strengthen the validation of novel targets from our platform. We look forward to collaborating with ProQR and its exciting RNA editing technologies.”